Global Fund: Progress Report 2010 - unaids

39 Bertozzi S, Padian N, Wegbreit J, et al. HIV/AIDS prevention and treatment.
In: Jamison DT, editor. Disease control priorities in developing countries.
New York: World Bank, World Health Organization, Fogarty International
Center of the National Institutes of Health; 2006.
40 Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment
in resource-poor settings: the case of Cote d’Ivoire. N Engl J Med.
2006;355(11):1141–53.
41 Freedberg KA, Kumarasamy N, Losina E, et al. Clinical impact and costeffectiveness
of antiretroviral therapy in India: starting criteria and
second-line therapy. AIDS. 2007;21(Suppl 4):S117–28.
42 Galarraga O, Colchero MA, Wamai RG, et al. HIV prevention cost-effectiveness:
a systematic review. BMC Public Health. 2009;9(Suppl.1):S5.
43 Commission on Macroeconomics and Health. Macroeconomics and health:
investing in health for economic development. Geneva: World Health
Organization; 2001.
44 Nachega JB, Leisegang R, Bishai D, et al. Association of antiretroviral therapy
adherence and health care costs. Ann Intern Med. 2010;152(1):18–25.
45 Otten M, Aregawi M, Were W, et al. Initial evidence of reduction of malaria
cases and deaths in Rwanda and Ethiopia due to rapid scale-up of malaria
prevention and treatment. Malar J. 2009;8:14.
46 Makombe SD, Jahn A, Tweya H, et al. A national survey of the impact
of rapid scale-up of antiretroviral therapy on health-care workers in
Malawi: effects on human resources and survival. Bull World Health Organ.
2007;85(11):851–7.
47 Hecht R, Alban A, Taylor K, et al. Putting it together: AIDS and the
Millennium Development Goals. PLoS Med. 2006;3(11):e455.
48 Beard J, Feeley F, Rosen S. Economic and quality of life outcomes of
antiretroviral therapy for HIV/AIDS in developing countries: a systematic
literature review. AIDS Care. 2009;21(11):1343–56.
49 Morineau G, Vun MC, Barennes H, et al. Survival and quality of life among
HIV-positive people on antiretroviral therapy in Cambodia. AIDS Patient
Care STDS. 2009;23(8):669–77.
50 Global Fund-supported Malawi HIV program: Unpublished data. Malawi:
Electricity Supply Corporation of Malawi; 2007.
51 Makombe SD, Jahn A, Tweya H, et al. A national survey of teachers on
antiretroviral therapy in Malawi: access, retention in therapy and survival.
PLoS One. 2007;2(7):e620.
52 Mermin J, Were W, Ekwaru JP, et al. Mortality in HIV-infected Ugandan
adults receiving antiretroviral therapy and survival of their HIV-uninfected
children: a prospective cohort study. Lancet. 2008;371(9614):752–9.
53 Maher D. Implications of the global financial crisis for the response to
diseases of poverty within overall health sector development: the case of
tuberculosis. Trop Med Int Health. 2010;15(1):11–17.
54 Laxminarayan R, Klein EY, Darley S, et al. Global investments in TB control:
economic benefits. Health Aff. 2009;28(4):w730–42.
55 Moatti JP, Marlink R, Luchini S, et al. Universal access to HIV treatment in
developing countries: going beyond the misinterpretations of the ‘costeffectiveness’
algorithm. AIDS. 2008;22(Suppl.1):S59–66.
56 Atun RA, Samyshkin Y, Drobniewski F, et al. Costs and outcomes of tuberculosis
control in the Russian Federation: retrospective cohort analysis.
Health Policy Plan. 2006;21(5):353–64.
57 Sinanovic E, Floyd K, Dudley L, et al. Cost and cost-effectiveness of
community-based care for tuberculosis in Cape Town, South Africa. Int
J Tuberc Lung Dis. 2003;7(9 Suppl 1):S56–62.
58 Okello D, Floyd K, Adatu F, et al. Cost and cost-effectiveness of community-based
care for tuberculosis patients in rural Uganda. Int J Tuberc Lung
Dis. 2003;7(9 Suppl 1):S72–9.
59 Nganda B, Wang’ombe J, Floyd K, et al. Cost and cost-effectiveness of
increased community and primary care facility involvement in tuberculosis
care in Machakos District, Kenya. Int J Tuberc Lung Dis. 2003;7(9 Suppl
1):S14–20.
CHAPTER 4
1 2009 key performance indicators [Internet]. Geneva: Global Fund to Fight
AIDS, Tuberculosis and Malaria; 2009 [cited 2010 Feb 23]. Available from:
http://www.theglobalfund.org/en/performance/kpi
2 The five year evaluation of the Global Fund [Internet]. Geneva: Global
Fund to Fight AIDS, Tuberculosis and Malaria; 2010 [cited 2010 Feb 23].
Available from: http://www.theglobalfund.org/en/terg/evaluations/5year
3 Partnership forum [Internet]. Geneva: Global Fund to Fight AIDS,
Tuberculosis and Malaria; 2010 [cited 2010 Feb 23]. Available from:
http://www.theglobalfund.org/en/partnershipforum
4 2004 partnership forum [Internet]. Geneva: Global Fund to Fight AIDS,
Tuberculosis and Malaria; 2004 [cited 2010 Feb 23]. Available from:
http://www.theglobalfund.org/en/partnershipforum/2004
5 2006 partnership forum [Internet]. Geneva: Global Fund to Fight AIDS,
Tuberculosis and Malaria; 2006 [cited 2010 Feb 23]. Available from:
http://www.theglobalfund.org/en/partnershipforum/2006
6 2008 partnership forum [Internet]. Geneva: Global Fund to Fight AIDS,
Tuberculosis and Malaria; 2008 [cited 2010 Feb 23]. Available from:
http://www.theglobalfund.org/en/partnershipforum/2008
7 Oomman N, Bernstein M, Rosenzweig S. Following the funding for HIV/
AIDS: a comparative analysis of the funding practices of PEPFAR, the
Global Fund and World Bank MAP in Mozambique, Uganda and Zambia.
Washington, DC: HIV/AIDS Monitor & Center for Global Development; 2007.
8 Committee on the Economics of Antimalarial Drugs. Saving lives, buying
time: economics of malaria drugs in an age of drug resistance.
Washington, DC: Institute of Medicine; 2004.